


This article was downloaded by:

On: 23 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713617200>

Synthetic Studies on Sialoglycoconjugates 89: Synthesis of Ganglioside GM₃ and KDN-GM₃ Containing Different Carbon-Chain Length Fatty Acyl Groups at the Ceramide Residue

Akira Hasegawa^a; Naomi Suzuki^a; Fumitaka Kozawa^a; Hideharu Ishida^a; Makoto Kiso^a

^a Department of Applied Bioorganic Chemistry, Gifu University, Gifu, Japan

To cite this Article Hasegawa, Akira , Suzuki, Naomi , Kozawa, Fumitaka , Ishida, Hideharu and Kiso, Makoto(1996) 'Synthetic Studies on Sialoglycoconjugates 89: Synthesis of Ganglioside GM₃ and KDN-GM₃ Containing Different Carbon-Chain Length Fatty Acyl Groups at the Ceramide Residue', *Journal of Carbohydrate Chemistry*, 15: 5, 639 – 648

To link to this Article: DOI: 10.1080/07328309608005680

URL: <http://dx.doi.org/10.1080/07328309608005680>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**SYNTHETIC STUDIES ON SIALOGLYCOCONJUGATES 89:
SYNTHESIS OF GANGLIOSIDE GM₃ AND KDN-GM₃
CONTAINING DIFFERENT CARBON-CHAIN LENGTH FATTY
ACYL GROUPS AT THE CERAMIDE RESIDUE**

Akira Hasegawa, Naomi Suzuki, Fumitaka Kozawa, Hideharu Ishida and
Makoto Kiso

Department of Applied Bioorganic Chemistry, Gifu University,
Gifu 501-11, Japan

Received January 27, 1996 - Final Form March 21, 1996

ABSTRACT


Ganglioside GM₃ and KDN-ganglioside GM₃, containing hexanoyl, decanoyl, and hexadecanoyl groups at the ceramide moiety have been synthesized. Selective reduction of the azido group in *O*-(methyl 5-acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-*D*-glycero- α -*D*-galacto-2-nonulopyranosylonate)-(2 \rightarrow 3)-*O*-(2,4-di-*O*-acetyl-6-*O*-benzoyl- β -*D*-galactopyranosyl)-(1 \rightarrow 4)-*O*-(3-*O*-acetyl-2,6-di-*O*-benzoyl- β -*D*-glucopyranosyl)-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-2-azido-3-*O*-benzoyl-4-octadecene-1,3-diol (**1**) and *O*-(methyl 4,5,7,8,9-penta-*O*-acetyl-3-deoxy-*D*-glycero- α -*D*-galacto-2-nonulopyranosylonate)-(2 \rightarrow 3)-*O*-(2,4-di-*O*-acetyl-6-*O*-benzoyl- β -*D*-galactopyranosyl)-(1 \rightarrow 4)-*O*-(3-*O*-acetyl-2,6-di-*O*-benzoyl- β -*D*-glucopyranosyl)-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-2-azido-3-*O*-benzoyl-4-octadecene-1,3-diol (**2**), coupling with hexanoic, decanoic, and hexadecanoic acids, *O*-deacylation, and de-esterification gave the title gangliosides GM₃ (**11**~**13**) and KDN-GM₃ (**14**~**16**) in good yields. On the other hand, *O*-deacylation of **1** and subsequent de-esterification gave 2-azido-sphingosine containing-GM₃ analogue **17**, which was converted into lyso-GM₃, in which no fatty acyl group was substituted at the sphingosine residue, by selective reduction of the azido group.

INTRODUCTION


Ganglioside GM₃ has various types of important biological functions,¹ and those activities are strictly related to the structure of sialic acid, oligosaccharide chain and fatty-acyl residue at the ceramide moiety. Gangliosides are potent inhibitors of cellular immune responses, and the structures of gangliosides greatly influence their activity.^{2,3} Recent studies using chemically synthesized gangliosides GM₃ and GM₄ and their analogues have shown^{4,5} the influence of certain structural details of their immunosuppressive activity as follows: 1) fatty acyl chain length at the ceramide moiety is an important factor for the activity 2) hydroxylation of the fatty acyl group decreases immunosuppressive activity 3) substitution of an *S*-glycosidic linkage for an *O*-glycosidic linkage in the sialic acid linkage does not alter its activity and 4) modification of the sialic acid structure variably influence the activity, since KDN (3-deoxy-D-*glycero*-D-*galacto*-2-nonulopyranosonic acid)-GM₃ and -GM₄ analogues retain potent activity, while other modifications such as 8-*epi*-GM₃ and 9-deoxy-GM₃ reduce immunosuppressive activity. In view of these facts, we describe here the synthesis of GM₃ and KDN-GM₃ each containing three different fatty-acyl groups hexanoyl, decanoyl, or hexadecanoyl at the ceramide moiety in order to clarify the relationship between fatty acyl chain length and immunosuppressive activity.

RESULTS AND DISCUSSION


For the synthesis of the desired ganglioside GM₃ and KDN-GM₃, we employed the intermediates (**1** and **2**) developed for the synthesis of GM₃⁶ and KDN-GM₃.⁷ Selective reduction^{6,8} of the azido group in compounds **1** and **2** with H₂S in 5:1 pyridine-water for 48 h at 0 °C gave the corresponding amines **3** and **4**, which on condensation with hexanoic, decanoic, and hexadecanoic acids, respectively, using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC) in CH₂Cl₂, gave the corresponding GM₃ and KDN-GM₃ derivatives **5**~**10** in high yields. Finally, *O*-deacylation of **5**~**10** with sodium methoxide in methanol, and subsequent saponification of the methyl ester group, yielded almost quantitatively the



- 1 $R^1 = N_3, R^2 = NHAc$
 2 $R^1 = N_3, R^2 = OAc$
 3 $R^1 = NH_2, R^2 = NHAc$
 4 $R^1 = NH_2, R^2 = OAc$
 5, 6, 7 $R^1 = NHCO(CH_2)_nMe, R^2 = NHAc, n = 4, 8, 14$
 8, 9, 10 $R^1 = NHCO(CH_2)_nMe, R^2 = OAc, n = 4, 8, 14$



- 11, 12, 13 $R = NHAc, n = 4, 8, 14$
 14, 15, 16 $R = OH, n = 4, 8, 14$



- 17 $R = N_3$
 18 $R = NH_2$

corresponding ganglioside GM₃ (11~13) and KDN-GM₃ (14~16) containing different fatty acyl groups at the ceramide moiety.

On the other hand, selective reduction of the azido group with H₂S in 17 prepared from 1 by *O*-deacylation and saponification of the methyl ester group, gave lyso-GM₃ (18) in 80% yield, in which no acyl group was substituted at the sphingosine moiety.

EXPERIMENTAL

General Procedures. Specific rotations were determined with a Union PM-201 polarimeter at 25 °C. ¹H NMR spectra were recorded with a JEOL JNM-GX 270 spectrometer. Preparative chromatography was performed on silica gel (Wako Chemical Co., 200 mesh) with the solvent systems specified. Concentrations were conducted *in vacuo*.

O-(Methyl 5-Acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-*D*-glycero- α -*D*-galacto-2-nonulopyranosylate)-(2 \rightarrow 3)-*O*-(2,4-di-*O*-acetyl-6-*O*-benzoyl- β -*D*-galactopyranosyl)-(1 \rightarrow 4)-*O*-(3-*O*-acetyl-2,6-di-*O*-benzoyl- β -*D*-glucopyranosyl)-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-3-*O*-benzoyl-2-hexanamido-4-octadecene-1,3-diol (5). Hydrogen sulfide was bubbled through a stirred solution of 16 (100 mg, 0.06 mmol) in aq 83% pyridine (6 mL) for 48 h at 0 °C. The reaction was monitored by TLC. After completion of the reaction, the mixture was concentrated, and the residue was stirred with hexanoic acid (21 mg, 0.18 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC) (57 mg, 0.3 mmol) in dry CH₂Cl₂ (5 mL) overnight at room temperature. Dichloromethane (30 mL) was added, and the mixture was washed with water, dried (Na₂SO₄) and concentrated. Column chromatography (60:1 CH₂Cl₂-MeOH) of the residue on silica gel (30 g) gave 5 (85 mg, 82%) as an amorphous mass: $[\alpha]_D +7.1^\circ$ (*c* 0.7, CHCl₃); ¹H NMR (CDCl₃) δ 0.85 (t, 6H, 2*Me*CH₂), 1.24 (s, 32H, 16CH₂), 1.84~2.18 (8s, 24H, 7AcO, AcN), 2.57 (dd, 1H, *J*_{gem} = 12.6 Hz, *J*_{3eq,4} = 4.4 Hz, H-3*beq*), 3.70 (s, 3H, MeO), 4.58 (dd, 1H, *J*_{2,3} = 10.3 Hz, *J*_{3,4} = 3.3 Hz, H-3*b*), 4.61 (d, 1H, *J*_{1,2} = 7.7 Hz, H-1*a*), 4.84 (d, 1H, *J*_{1,2} = 8.1 Hz, H-1*b*), 5.02 (d, 1H, H-4*b*), 5.15

(dd, 1H, H-2b), 5.19 (dd, 1H, $J_{2,3} = 8.0$ Hz, H-2a), 5.38 (dd, 1H, $J_{6,7} = 2.9$ Hz, $J_{7,8} = 8.8$ Hz, H-7c), 5.47 (br t, 1H, $J_{3,4} = 9.7$ Hz, H-3a), 5.65 (d, 1H, $J_{5,NH} = 9.0$ Hz, NH), 5.76 (m, 1H, H-5 of sphingosine), and 7.25-8.06 (m, 20H, 4Ph).

Anal. Calcd for $C_{90}H_{116}N_2O_{32}$ (1737.0): C, 62.21; H, 6.73; N, 1.61. Found: C, 62.33; H, 6.81; N, 1.56.

***O*-(Methyl 5-Acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosylonate)-(2 \rightarrow 3)-*O*-(2,4-di-*O*-acetyl-6-*O*-benzoyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-*O*-(3-*O*-acetyl-2,6-di-*O*-benzoyl- β -D-glucopyranosyl)-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-3-*O*-benzoyl-2-decanamido-4-octadecene-1,3-diol (6).** The azido group in **1** (100 mg, 0.06 mmol) was converted into amine as described for **5**, which was then condensed with decanoic acid (31 mg, 0.18 mmol) in the presence of WSC (57 mg, 0.3 mmol), to give **6** (85 mg, 79%) as an amorphous mass: $[\alpha]_D +6.5^\circ$ (*c* 0.8, $CHCl_3$); 1H NMR ($CDCl_3$) δ 0.89 (t, 6H, 2*MeCH*₂), 1.28 (s, 40H, 20*CH*₂), 1.75 (t, 1H, $J_{gem} = J_{3ax,4} = 12.5$ Hz, H-3*cax*), 1.85-2.27 (8s, 24H, 7AcO, AcN), 2.67 (dd, 1H, $J_{3eq,4} = 4.9$ Hz, H-3*ceq*), 3.67 (dd, 1H, $J_{5,6} = 10.4$ Hz, $J_{6,7} = 3.6$ Hz, H-6c), 3.78 (s, 3H, MeO), 4.67 (dd, 1H, $J_{2,3} = 9.7$ Hz, $J_{3,4} = 3.1$ Hz, H-3b), 4.70 (d, 1H, $J_{1,2} = 7.5$ Hz, H-1a), 4.93 (d, 1H, $J_{1,2} = 7.9$ Hz, H-1b), 5.02 (d, 1H, H-4b), 5.24 (dd, 1H, H-2b), 5.33 (t, 1H, $J_{2,3} = 7.5$ Hz, H-2a), 5.45 (dd, 1H, $J_{7,8} = 6.8$ Hz, H-7c), 5.58 (br t, 1H, $J_{3,4} = 7.0$ Hz, H-3a), 5.76 (d, 1H, $J_{5,NH} = 9.8$ Hz, NH), 5.84 (m, 1H, H-5 of sphingosine), and 7.34-8.14 (m, 20H, 4Ph).

Anal. Calcd for $C_{94}H_{124}N_2O_{32}$ (1794.0): C, 62.93; H, 6.97; N, 1.56. Found: C, 62.77; H, 6.95; N, 1.49.

***O*-(Methyl 5-Acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosylonate)-(2 \rightarrow 3)-*O*-(2,4-di-*O*-acetyl-6-*O*-benzoyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-*O*-(3-*O*-acetyl-2,6-di-*O*-benzoyl- β -D-glucopyranosyl)-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-3-*O*-benzoyl-2-hexadecanamido-4-octadecene-1,3-diol (7).** Reduction of the azido group in **1** (100 mg, 0.06 mmol) and subsequent coupling with hexadecanoic acid (46 mg, 0.18 mmol) using WSC (57 mg, 0.3 mmol), according to the procedure described for **5**, gave compound **7** (95.5 mg, 85%) as an amorphous mass: $[\alpha]_D +6.2^\circ$ (*c* 1.9, $CHCl_3$); 1H NMR ($CDCl_3$) δ 0.96 (t, 6H, 2*MeCH*₂), 1.30 (s, 52H, 26*CH*₂), 1.91-2.26 (8s,

24H, 7AcO, AcN), 1.78 (t, 1H, $J_{gem} = J_{3ax,4} = 12.5$ Hz, H-3cax), 2.64 (dd, 1H, $J_{3eq,4} = 4.4$ Hz, H-3ceq), 3.67 (dd, 1H, $J_{5,6} = 10.8$ Hz, $J_{6,7} = 2.7$ Hz, H-6c), 3.77 (s, 3H, MeO), 4.68 (dd, 1H, $J_{2,3} = 9.9$ Hz, $J_{3,4} = 3.5$ Hz, H-3b), 4.70 (d, 1H, $J_{1,2} = 7.7$ Hz, H-1a), 4.93 (d, 1H, $J_{1,2} = 7.9$ Hz, H-1b), 5.07 (d, 1H, H-4b), 5.24 (dd, 1H, H-2b), 5.33 (dd, 1H, $J_{2,3} = 8.1$ Hz, H-2a), 5.45 (dd, 1H, $J_{7,8} = 7.1$ Hz, H-7), 5.57 (dd, 1H, $J_{3,4} = 7.0$ Hz, H-3a), 5.85 (m, 1H, H-5 of sphingosine), and 7.36–8.14 (m, 20H, 4Ph).

Anal. Calcd for $C_{100}H_{136}N_2O_{32}$ (1878.2): C, 63.95; H, 7.30; N, 1.49. Found: C, 63.72; H, 7.45; N, 1.50.

***O*-(Methyl 4,5,7,8,9-Penta-*O*-acetyl-3-deoxy-*D*-glycero- α -*D*-galacto-2-nonulopyranosylonate)-(2 \rightarrow 3)-*O*-(2,4-di-*O*-acetyl-6-*O*-benzoyl- β -*D*-galactopyranosyl)-(1 \rightarrow 4)-*O*-(3-*O*-acetyl-2,6-di-*O*-benzoyl- β -*D*-glucopyranosyl)-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-3-*O*-benzoyl-2-hexanamido-4-octadecene-1,3-diol (8).** Reduction of the azido group in **2**⁷ (111.6 mg, 0.07 mmol) and subsequent coupling with hexanoic acid (16.5 mg, 0.14 mmol) using WSC (27 mg), according to the procedure described for **5**, gave compound **8** (86 mg, 70%) as an amorphous mass: $[\alpha]_D +11.5^\circ$ (*c* 0.4, $CHCl_3$); 1H NMR ($CDCl_3$) δ 0.86 (t, 6H, 2*MeCH*₂), 1.25 (s, 32H, 16*CH*₂), 1.96–2.15 (8s, 24H, 8AcO), 2.63 (dd, 1H, $J_{gem} = 12.8$ Hz, $J_{3eq,4} = 4.3$ Hz, H-3ceq), 3.74 (s, 3H, MeO), 4.60 (d, 1H, $J_{1,2} = 7.7$ Hz, H-1a), 5.19 (dd, 1H, $J_{2,3} = 9.8$ Hz, H-2a), 5.57 (m, 1H, H-8c), 5.78 (dt, 1H, $J_{4,5} = 14.8$ Hz, $J_{5,6} = J_{5,6}' = 6.6$ Hz, H-5 of sphingosine), and 7.25–8.06 (m, 20H, 4Ph).

Anal. Calcd for $C_{90}H_{115}NO_{33}$ (1738.9): C, 62.17; H, 6.67; N, 0.81. Found: C, 62.03; H, 6.85; N, 0.97.

***O*-(Methyl 4,5,7,8,9-Penta-*O*-acetyl-3-deoxy-*D*-glycero- α -*D*-galacto-2-nonulopyranosylonate)-(2 \rightarrow 3)-*O*-(2,4-di-*O*-acetyl-6-*O*-benzoyl- β -*D*-galactopyranosyl)-(1 \rightarrow 4)-*O*-(3-*O*-acetyl-2,6-di-*O*-benzoyl- β -*D*-glucopyranosyl)-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-3-*O*-benzoyl-2-decanamido-4-octadecene-1,3-diol (9).** Reduction of the azido group in **2** (102 mg, 0.061 mmol) and subsequent coupling with decanoic acid (21 mg, 0.12 mmol) using WSC (23.5 mg), according to the procedure described for **5**, gave compound **9** (76 mg, 69%) as an amorphous mass: $[\alpha]_D +9.2^\circ$ (*c* 0.3, $CHCl_3$); 1H NMR ($CDCl_3$) δ 0.89 (t, 6H, 2*MeCH*₂), 1.26 (s, 40H, 20*CH*₂), 1.87–2.21 (8s, 24H, 8AcO), 2.65 (dd, 1H,

$J_{gem} = 12.5$ Hz, $J_{3eq,4} = 4.5$ Hz, H-3 $_{ceq}$), 3.78 (s, 3H, MeO), 4.63 (d, 1H, $J_{1,2} = 7.7$ Hz, H-1a), 4.91 (d, 1H, $J_{1,2} = 7.9$ Hz, H-1b), 5.22 (dd, 1H, $J_{2,3} = 9.1$ Hz, H-2a), 5.45 (dd, 1H, $J_{6,7} = 2.0$ Hz, $J_{7,8} = 7.9$ Hz, H-7c), 5.57 (m, 1H, H-8c), 5.80 (m, 1H, H-5 of sphingosine), and 7.31~8.09 (m, 20H, 4Ph).

Anal. Calcd for $C_{94}H_{123}NO_{33}$ (1795.0): C, 62.90; H, 6.91; N, 0.78. Found: C, 62.86; H, 7.15; N, 0.83.

***O*-(Methyl 4,5,7,8,9-Penta-*O*-acetyl-3-deoxy-D-glycero- α -D-galacto-2-nonulopyranosylonate)-(2 \rightarrow 3)-*O*-(2,4-di-*O*-acetyl-6-*O*-benzoyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-*O*-(3-*O*-acetyl-2,6-di-*O*-benzoyl- β -D-glucopyranosyl)-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-3-*O*-benzoyl-2-hexadecanamido-4-octadecene-1,3-diol (10).** Reduction of the azido group in **2** (182.5 mg, 0.11 mmol) and subsequent coupling with hexadecanoic acid (56 mg, 0.22 mmol) using WSC (42 mg, 0.22 mmol), according to the procedure for **5**, gave compound **10** (162 mg, 79%) as an amorphous mass: $[\alpha]_D +10.1^\circ$ (c 0.5, $CHCl_3$); 1H NMR ($CDCl_3$) δ 0.88 (t, 6H, 2*Me*CH₂), 1.26 (s, 52H, 26CH₂), 1.97~2.17 (8s, 24H, 8AcO), 2.64 (dd, 1H, $J_{gem} = 12.7$ Hz, H-3 $_{ceq}$), 3.74 (s, 3H, MeO), 4.63 (d, 1H, $J_{1,2} = 7.9$ Hz, H-1a), 4.90 (d, 1H, $J_{1,2} = 8.2$ Hz, H-1b), 5.22 (dd, 1H, $J_{2,3} = 9.3$ Hz, H-2b), 5.57 (m, 1H, H-8c), 5.78 (dt, 1H, $J_{4,5} = 15.2$ Hz, $J_{5,6} = J_{5,6'} = 6.6$ Hz, H-5 of sphingosine), and 7.25-8.07 (m, 20H, 4Ph).

Anal. Calcd for $C_{100}H_{135}NO_{33}$ (1879.2): C, 63.92; H, 7.24; N, 0.75. Found: C, 64.11; H, 7.20; N, 0.81.

***O*-(5-Acetamido-3,5-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosylonic acid)-(2 \rightarrow 3)-*O*- β -D-galactopyranosyl-(1 \rightarrow 4)-*O*- β -D-glucopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-2-hexanamido-4-octadecene-1,3-diol (11).** To a solution of **5** (85.1 mg, 0.05 mmol) in MeOH (5 mL) was added NaOMe (20 mg) and the mixture was stirred overnight at 40 °C; the course of the reaction was monitored by TLC. Water (0.2 mL) was added to the mixture, and this was stirred overnight at room temperature and then treated with Amberlite IR-120 (H⁺) resin and filtered. The resin was washed with 1:1 $CHCl_3$ -MeOH, and the combined filtrate and washings was concentrated. Column chromatography (1:1 $CHCl_3$ -MeOH) of the residue on Sephadex LH-20 (20 g) gave **11** (48.6 mg, 98%) as an amorphous mass: $[\alpha]_D +6.5^\circ$

(*c* 0.5, 1:1 CHCl₃-MeOH); ¹H NMR (1:2 CDCl₃-CD₃OD) δ 0.99 (t, 6H, 2*Me*CH₂), 1.38 (s, 32H, 16CH₂), 2.10 (s, 3H, AcN), 2.27 (br t, 1H, H-3*ceq*), 4.15 (d, 1H, J_{1,2} = 7.3 Hz, H-1a), 4.40 (d, 1H, J_{1,2} = 7.7 Hz, H-1b), and 5.74 (m, 1H, H-5 of sphingosine).

Anal. Calcd for C₄₇H₈₄N₂O₂₁ (1013.2): C, 55.72; H, 8.36; N, 2.77. Found: C, 55.77; H, 8.49; N, 2.70.

***O*-(5-Acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2→3)-*O*-β-D-galactopyranosyl-(1→4)-*O*-β-D-glucopyranosyl-(1→1)-(2*S*,3*R*,4*E*)-2-decanamido-4-octadecene-1,3-diol (12).** The *O*-acyl and methyl ester groups in **6** (40 mg, 0.02 mmol) were removed, as described for **11**, to give compound **12** (22.4 mg, 93%) as an amorphous mass: [α]_D +4.5° (*c* 0.5, 1:1 CHCl₃-MeOH); ¹H NMR (1:2 CDCl₃-CD₃OD) δ 0.99 (t, 6H, 2*Me*CH₂), 1.39 (s, 40H, 20CH₂), 1.68 (br t, 1H, H-3*cax*), 2.11 (s, 3H, AcN), 2.27 (br dd, 1H, H-3*ceq*), 3.99 (d, 1H, J_{1,2} = 7.3 Hz, H-1a), 4.40 (d, 1H, J_{1,2} = 7.7 Hz, H-1b), and 5.66 (m, 1H, H-5 of sphingosine).

Anal. Calcd for C₅₁H₉₂N₂O₂₁ (1069.3): C, 57.29; H, 8.67; N, 2.62. Found: C, 57.13; H, 8.90; N, 2.62.

***O*-(5-Acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2→3)-*O*-β-D-galactopyranosyl-(1→4)-*O*-β-D-glucopyranosyl-(1→1)-(2*S*,3*R*,4*E*)-2-hexadecanamido-4-octadecene-1,3-diol (13).** The *O*-acyl and methyl ester groups in **7** (95.4 mg, 0.05 mmol) were removed, as described for **11**, to give compound **13** (59 mg, quantitative) as an amorphous mass: [α]_D +1.5° (*c* 1.2, 1:1 CHCl₃-MeOH); ¹H NMR (1:2 CDCl₃-CD₃OD) δ 0.89 (t, 6H, 2*Me*CH₂), 1.24 (s, 52H, 26CH₂), 1.67 (br t, 1H, H-3*cax*), 1.91 (s, 3H, AcN), 2.07 (br dd, 1H, H-3*ceq*), 3.95 (d, 1H, J_{1,2} = 7.9 Hz, H-1a), 4.20 (d, 1H, J_{1,2} = 7.7 Hz, H-1b), and 5.30–5.61 (m, 2H, H-4,5 of sphingosine).

Anal. Calcd for C₅₇H₁₀₄N₂O₂₁ (1153.5): C, 59.35; H, 9.09; N, 2.43. Found: C, 59.20; H, 9.18; N, 2.55.

***O*-(3-Deoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2→3)-*O*-β-D-galactopyranosyl-(1→4)-*O*-β-D-glucopyranosyl-(1→1)-(2*S*,3*R*,4*E*)-2-hexanamido-4-octadecene-1,3-diol (14).** The *O*-acyl and

methyl ester groups in **8** (60.5 mg, 0.035 mmol) were removed, as described for **11**, to give compound **14** (34.3 mg, quantitative) as an amorphous mass: $[\alpha]_D -7.1^\circ$ (*c* 0.8, 1:1 CHCl₃-MeOH); ¹H NMR [100:1 (CD₃)₂SO-H₂O] δ 0.88 (t, 6H, 2*MeCH*₂), 1.24 (s, 32H, 16CH₂), 2.06 (br t, 1H, H-3*cax*), 2.43 (br dd, 1H, H-3*ceq*), 4.16 (d, 1H, J_{1,2} = 7.5 Hz, H-1a), 4.24 (d, 1H, J_{1,2} = 7.6 Hz, H-1b), 5.36 (dd, 1H, J_{3,4} = 6.8 Hz, J_{4,5} = 14.8 Hz, H-4 of sphingosine), and 5.57 (dt, 1H, J_{5,6} = J_{5,6'} = 6.1 Hz, H-5 of sphingosine).

Anal. Calcd for C₄₅H₈₁NO₂₁ (972.2): C, 55.60; H, 8.40; N, 1.44. Found: C, 55.43; H, 8.59; N, 1.41.

O-(3-Deoxy-D-glycero- α -D-galacto-2-nonulopyranosylonic acid)-(2 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O- β -D-glucopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-2-decanamido-4-octadecene-1,3-diol (**15**). *O*-Deacylation and saponification of **9** (58 mg, 0.032 mmol), as described for **11**, yielded amorphous **15** (37.5 mg, quantitative): $[\alpha]_D -7.9^\circ$ (*c* 0.8, 1:1 CHCl₃-MeOH); ¹H NMR [100:1 (CD₃)₂SO-H₂O] δ 0.87 (t, 6H, 2*MeCH*₂), 1.24 (s, 40H, 20CH₂), 2.05 (br t, 1H, H-3*cax*), 2.63 (br dd, 1H, H-3*ceq*), 4.16 (d, 1H, J_{1,2} = 7.6 Hz, H-1a), 4.20 (d, 1H, J_{1,2} = 7.9 Hz, H-1b), 5.35 (dd, 1H, J_{3,4} = 6.0 Hz, J_{4,5} = 15.4 Hz, H-4 of sphingosine), and 5.56 (dt, 1H, J_{5,6} = J_{5,6'} = 6.1 Hz, H-5 of sphingosine).

Anal. Calcd for C₄₉H₈₉NO₂₁ (1028.3): C, 57.23; H, 8.72; N, 1.36. Found: C, 57.05; H, 8.93; N, 1.35.

O-(3-Deoxy-D-glycero- α -D-galacto-2-nonulopyranosylonic acid)-(2 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O- β -D-glucopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-2-hexadecanamido-4-octadecene-1,3-diol (**16**). *O*-Deacylation and saponification of **10** (70.6 mg, 0.038 mmol), as described for **11**, yielded amorphous **16** (39.8 mg, 94%): $[\alpha]_D -7.3^\circ$ (*c* 0.8, 1:1 CHCl₃-MeOH); ¹H NMR [100:1 (CD₃)₂SO-H₂O] δ 0.86 (t, 6H, 2*MeCH*₂), 1.23 (s, 52H, 26CH₂), 2.03 (br t, 1H, H-3*cax*), 2.53 (br dd, 1H, H-3*ceq*), 4.16 (d, 1H, J_{1,2} = 7.9 Hz, H-1a), 4.23 (d, 1H, J_{1,2} = 7.5 Hz, H-2b), 5.35 (dd, 1H, J_{3,4} = 6.1 Hz, J_{4,5} = 15.2 Hz, H-4 of sphingosine), and 5.54 (dt, 1H, J_{5,6} = J_{5,6'} = 6.4 Hz, H-5 of sphingosine).

Anal. Calcd for C₅₅H₁₀₁NO₂₁ (1112.4): C, 59.39; H, 9.15; N, 1.26. Found: C, 59.42; H, 9.33; N, 1.24.

***O*-(5-Acetamido-3,5-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosylonic acid)-(2 \rightarrow 3)-*O*- β -D-galactopyranosyl-(1 \rightarrow 4)-*O*- β -D-glucopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-2-amino-4-octadecene-1,3-diol (lyso-GM3) (18).** Hydrogen sulfide was bubbled through a stirred solution of 17, prepared from 1 by *O*-deacylation and subsequent de-esterification (49.5 mg, 0.06 mmol) in aq 83% pyridine (12 mL) for 3 days at room temperature. The reaction was monitored by TLC. After completion of the reaction, the mixture was concentrated to a syrup which was chromatographed on a column of Sephadex LH-20 (20 g) with 1:1 CHCl₃-MeOH to give 18 (39 g, 80%) as an amorphous mass: $[\alpha]_D -4.5^\circ$ (*c* 0.5, 1:1 CHCl₃-MeOH); ¹H NMR (1:1 CDCl₃-CD₃OD) δ 0.86 (t, 3H, 2*Me*CH₂), 1.25 (s, 22H, 11CH₂), 1.91 (s, 3H, AcN), 2.78 (br dd, 1H, H-3*ceq*), 4.20 (d, 1H, J_{1,2} = 7.5 Hz, H-1*a*), 4.25 (d, 1H, J_{1,2} = 7.9 Hz, H-1*b*), 5.44 (dd, 1H, J_{3,4} = 6.0 Hz, J_{4,5} = 15.2 Hz, H-4 of sphingosine), and 5.73 (dt, 1H, J_{5,6} = J_{5,6'} = 6.6 Hz, H-5 of sphingosine).

Anal. Calcd for C₄₁H₇₄N₂O₂₀ (915.0): C, 53.82; H, 8.15; N, 2.62. Found: C, 53.61; H, 8.20; N, 2.56.

ACKNOWLEDGMENT

This work was supported in part by a Grant-in-Aid (No. 07273226 and No. 05274102) for Scientific Research on Priority Areas from the Ministry of Education, Science and Culture of Japan.

REFERENCES

1. A. Hasegawa, N. Suzuki, H. Ishida and M. Kiso, *J. Carbohydr. Chem.*, (preceding paper) references cited therein.
2. S. Ladisch, B. Gillard, C. Wong and L. Ulsh, *Cancer Res.*, **43**, 3808 (1983).
3. S. Ladisch, R. Li and E. Olson, *Proc. Natl. Acad. Sci. USA*, **91**, 1974 (1994).
4. S. Ladisch, A. Hasegawa, R. Li and M. Kiso, *Biochem. Biophys. Res. Commun.*, **203**, 1102 (1994).
5. S. Ladisch, A. Hasegawa, R. Li and M. Kiso, *Biochemistry*, **34**, 1197 (1995).
6. T. Murase, H. Ishida, M. Kiso and A. Hasegawa, *Carbohydr. Res.*, **188**, 71 (1989).
7. T. Terada, M. Kiso and A. Hasegawa, *J. Carbohydr. Chem.*, **12**, 425 (1993).
8. T. Adachi, Y. Yamada, I. Inoue and M. Saneyoshi, *Synthesis*, 45 (1977).